Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 205 results for physiotherapy

  1. GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  2. Medical technologies advisory committee members

    physiotherapist with Health and Care Professions Council and Chartered Society of Physiotherapy respectively. Dr Richard Packer...

  3. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  4. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....

  5. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  6. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  7. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)

    This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.

  8. Devices for remote monitoring of Parkinson's disease (DG51)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease

  9. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  10. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  11. Velmanase alfa for treating alpha-mannosidosis (HST29)

    Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.

  12. Biodegradable subacromial spacer insertion for rotator cuff tears (IPG775)

    Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears. This involves inserting a balloon-shaped device between the top of the shoulder blade and the upper arm bone to reduce pain and improve shoulder function.

  13. People who have had a stroke should be offered additional rehabilitation to help them recover NICE says in updated guidance

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover, NICE has said in updated guidance published today.

  14. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  15. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.